{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T05:57:31Z","timestamp":1782712651946,"version":"3.54.5"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,16]]},"DOI":"10.7759\/cureus.67014","type":"journal-article","created":{"date-parts":[[2024,8,16]],"date-time":"2024-08-16T16:52:18Z","timestamp":1723827138000},"source":"Crossref","is-referenced-by-count":5,"title":["Investigating Interleukin-6 Levels in Type 2 Diabetes Mellitus Patients With and Without Diabetic Nephropathy"],"prefix":"10.7759","author":[{"given":"Vutukuru Kalyan Kumar","family":"Reddy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Govind","family":"Shiddapur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilesh","family":"Jagdale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohith Prakash","family":"Kondapalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saimounika","family":"Adapa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2017.10.026","article-title":"Update on diabetic nephropathy: core curriculum 2018","volume":"71","author":"Umanath K","year":"2018","unstructured":"Umanath K, Lewis JB. Update on diabetic nephropathy: core curriculum 2018. Am J Kidney Dis. 2018, 71:884-95. 10.1053\/j.ajkd.2017.10.026","journal-title":"Am J Kidney Dis"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-1296","article-title":"Diabetic kidney disease: a report from an ADA Consensus Conference","volume":"37","author":"Tuttle KR","year":"2014","unstructured":"Tuttle KR, Bakris GL, Bilous RW, et al.. Diabetic kidney disease: a report from an ADA Consensus Conference. Diabetes Care. 2014, 37:2864-83. 10.2337\/dc14-1296","journal-title":"Diabetes Care"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-02421-9","article-title":"Assessment of the diagnostic value of different biomarkers in relation to various stages of diabetic nephropathy in type 2 diabetic patients","volume":"7","author":"Al-Rubeaan K","year":"2017","unstructured":"Al-Rubeaan K, Siddiqui K, Al-Ghonaim MA, Youssef AM, Al-Sharqawi AH, AlNaqeb D. Assessment of the diagnostic value of different biomarkers in relation to various stages of diabetic nephropathy in type 2 diabetic patients. Sci Rep. 2017, 7:2684. 10.1038\/s41598-017-02421-9","journal-title":"Sci Rep"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2011.51","article-title":"Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy","volume":"7","author":"Navarro-Gonz\u00e1lez JF","year":"2011","unstructured":"Navarro-Gonz\u00e1lez JF, Mora-Fern\u00e1ndez C, Muros de Fuentes M, Garc\u00eda-P\u00e9rez J. Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy. Nat Rev Nephrol. 2011, 7:327-40. 10.1038\/nrneph.2011.51","journal-title":"Nat Rev Nephrol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2005.00200.x","article-title":"IL-10, IL-6, and TNF-alpha: central factors in the altered cytokine network of uremia--the good, the bad, and the ugly","volume":"67","author":"Stenvinkel P","year":"2005","unstructured":"Stenvinkel P, Ketteler M, Johnson RJ, et al.. IL-10, IL-6, and TNF-alpha: central factors in the altered cytokine network of uremia--the good, the bad, and the ugly. Kidney Int. 2005, 67:1216-33. 10.1111\/j.1523-1755.2005.00200.x","journal-title":"Kidney Int"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2008.202","article-title":"An IL-6 haplotype on human chromosome 7p21 confers risk for impaired renal function in type 2 diabetic patients","volume":"74","author":"Ng DP","year":"2008","unstructured":"Ng DP, Nurbaya S, Ye SH, Krolewski AS. An IL-6 haplotype on human chromosome 7p21 confers risk for impaired renal function in type 2 diabetic patients. Kidney Int. 2008, 74:521-7. 10.1038\/ki.2008.202","journal-title":"Kidney Int"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2013.12.135","article-title":"Assessment of the effects of 174G\/C polymorphism on interleukin 6 genes on macrovascular complications in patients with type 2 diabetes mellitus","volume":"172","author":"Papaoikonomou S","year":"2014","unstructured":"Papaoikonomou S, Tousoulis D, Tentolouris N, Miliou A, Papageorgiou N, Synetos A, Stefanadis C. Assessment of the effects of 174G\/C polymorphism on interleukin 6 genes on macrovascular complications in patients with type 2 diabetes mellitus. Int J Cardiol. 2014, 172:e190-1. 10.1016\/j.ijcard.2013.12.135","journal-title":"Int J Cardiol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3109\/00365513.2011.598944","article-title":"The relationship between inflammation, endothelial dysfunction and proteinuria in patients with diabetic nephropathy","volume":"71","author":"Taslipinar A","year":"2011","unstructured":"Taslipinar A, Yaman H, Yilmaz MI, et al.. The relationship between inflammation, endothelial dysfunction and proteinuria in patients with diabetic nephropathy. Scand J Clin Lab Invest. 2011, 71:606-12. 10.3109\/00365513.2011.598944","journal-title":"Scand J Clin Lab Invest"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2017.03.059","article-title":"Hepatocellular carcinomas originate predominantly from hepatocytes and benign lesions from hepatic progenitor cells","volume":"19","author":"Tummala KS","year":"2017","unstructured":"Tummala KS, Brandt M, Teijeiro A, Gra\u00f1a O, Schwabe RF, Perna C, Djouder N. Hepatocellular carcinomas originate predominantly from hepatocytes and benign lesions from hepatic progenitor cells. Cell Rep. 2017, 19:584-600. 10.1016\/j.celrep.2017.03.059","journal-title":"Cell Rep"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.2337\/db05-1404","article-title":"Interleukin-6 increases insulin-stimulated glucose disposal in humans and glucose uptake and fatty acid oxidation in vitro via AMP-activated protein kinase","volume":"55","author":"Carey AL","year":"2006","unstructured":"Carey AL, Steinberg GR, Macaulay SL, et al.. Interleukin-6 increases insulin-stimulated glucose disposal in humans and glucose uptake and fatty acid oxidation in vitro via AMP-activated protein kinase. Diabetes. 2006, 55:2688-97. 10.2337\/db05-1404","journal-title":"Diabetes"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.90100.2007","article-title":"Muscle as an endocrine organ: focus on muscle-derived interleukin-6","volume":"88","author":"Pedersen BK","year":"2008","unstructured":"Pedersen BK, Febbraio MA. Muscle as an endocrine organ: focus on muscle-derived interleukin-6. Physiol Rev. 2008, 88:1379-406. 10.1152\/physrev.90100.2007","journal-title":"Physiol Rev"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2513","article-title":"Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells","volume":"17","author":"Ellingsgaard H","year":"2011","unstructured":"Ellingsgaard H, Hauselmann I, Schuler B, et al.. Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells. Nat Med. 2011, 17:1481-9. 10.1038\/nm.2513","journal-title":"Nat Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.53.3.693","article-title":"Inflammatory markers and risk of developing type 2 diabetes in women","volume":"53","author":"Hu FB","year":"2004","unstructured":"Hu FB, Meigs JB, Li TY, Rifai N, Manson JE. Inflammatory markers and risk of developing type 2 diabetes in women. Diabetes. 2004, 53:693-700. 10.2337\/diabetes.53.3.693","journal-title":"Diabetes"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s10787-018-0458-0","article-title":"IL-6 signalling pathways and the development of type 2 diabetes","volume":"26","author":"Akbari M","year":"2018","unstructured":"Akbari M, Hassan-Zadeh V. IL-6 signalling pathways and the development of type 2 diabetes. Inflammopharmacology. 2018, 26:685-98. 10.1007\/s10787-018-0458-0","journal-title":"Inflammopharmacology"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.54.suppl_2.s114","article-title":"Interleukin-6 and diabetes: the good, the bad, or the indifferent?","volume":"54 Suppl 2","author":"Kristiansen OP","year":"2005","unstructured":"Kristiansen OP, Mandrup-Poulsen T. Interleukin-6 and diabetes: the good, the bad, or the indifferent?. Diabetes. 2005, 54 Suppl 2:S114-24. 10.2337\/diabetes.54.suppl_2.s114","journal-title":"Diabetes"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1186\/2047-783x-15-s2-120","article-title":"Proinflammatory cytokines Il-6 and TNF-\u03b1 and the development of inflammation in obese subjects","volume":"15 Suppl 2","author":"Popko K","year":"2010","unstructured":"Popko K, Gorska E, Stelmaszczyk-Emmel A, et al.. Proinflammatory cytokines Il-6 and TNF-\u03b1 and the development of inflammation in obese subjects. Eur J Med Res. 2010, 15 Suppl 2:120-2. 10.1186\/2047-783x-15-s2-120","journal-title":"Eur J Med Res"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.52.3.812","article-title":"Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study","volume":"52","author":"Spranger J","year":"2003","unstructured":"Spranger J, Kroke A, M\u00f6hlig M, et al.. Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes. 2003, 52:812-7. 10.2337\/diabetes.52.3.812","journal-title":"Diabetes"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00405","article-title":"Interleukin-6 signaling pathway and its role in kidney disease: an update","volume":"8","author":"Su H","year":"2017","unstructured":"Su H, Lei CT, Zhang C. Interleukin-6 signaling pathway and its role in kidney disease: an update. Front Immunol. 2017, 8:405. 10.3389\/fimmu.2017.00405","journal-title":"Front Immunol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.628289","article-title":"Inflammatory cytokines in diabetic kidney disease: pathophysiologic and therapeutic implications","volume":"7","author":"Donate-Correa J","year":"2020","unstructured":"Donate-Correa J, Ferri CM, S\u00e1nchez-Quintana F, et al.. Inflammatory cytokines in diabetic kidney disease: pathophysiologic and therapeutic implications. Front Med (Lausanne). 2020, 7:628289. 10.3389\/fmed.2020.628289","journal-title":"Front Med (Lausanne)"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.2337\/diab.44.10.1233","article-title":"In situ hybridization of interleukin 6 in diabetic nephropathy","volume":"44","author":"Suzuki D","year":"1995","unstructured":"Suzuki D, Miyazaki M, Naka R, et al.. In situ hybridization of interleukin 6 in diabetic nephropathy. Diabetes. 1995, 44:1233-8. 10.2337\/diab.44.10.1233","journal-title":"Diabetes"},{"key":"ref21","article-title":"The role of serum interleukin-6 level in type 2 diabetic nephropathy","volume":"16","author":"Huong PT","year":"2021","unstructured":"Huong PT, Nguyen CTT, Binh NG, et al.. The role of serum interleukin-6 level in type 2 diabetic nephropathy. Res J Biotech. 2021, 16:1-3.","journal-title":"Res J Biotech"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-018-0853-1","article-title":"Predictive value of spot versus 24-hour measures of proteinuria for death, end-stage kidney disease or chronic kidney disease progression","volume":"19","author":"Ying T","year":"2018","unstructured":"Ying T, Clayton P, Naresh C, Chadban S. Predictive value of spot versus 24-hour measures of proteinuria for death, end-stage kidney disease or chronic kidney disease progression. BMC Nephrol. 2018, 19:55. 10.1186\/s12882-018-0853-1","journal-title":"BMC Nephrol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.5414\/CN110223","article-title":"Serum interleukin-6 levels predict kidney disease progression in diabetic nephropathy","volume":"97","author":"Sanchez-Alamo B","year":"2022","unstructured":"Sanchez-Alamo B, Shabaka A, Cachofeiro V, Cases-Corona C, Fernandez-Juarez G. Serum interleukin-6 levels predict kidney disease progression in diabetic nephropathy. Clin Nephrol. 2022, 97:1-9. 10.5414\/CN110223","journal-title":"Clin Nephrol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/275272-investigating-interleukin-6-levels-in-type-2-diabetes-mellitus-patients-with-and-without-diabetic-nephropathy","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,16]],"date-time":"2024-08-16T16:52:23Z","timestamp":1723827143000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/275272-investigating-interleukin-6-levels-in-type-2-diabetes-mellitus-patients-with-and-without-diabetic-nephropathy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,16]]},"references-count":23,"URL":"https:\/\/doi.org\/10.7759\/cureus.67014","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8,16]]}}}